TAGRISSO contains the active substance osimertinib, which belongs to the protein kinase inhibitor class of anticancer medicines. TAGRISSO is used to treat adults with a type of lung cancer called ‘non-small cell lung cancer’ when the tumour has a defect (mutation) in a gene called EGFR (epidermal growth factor receptor). It is used when your cancer is advanced and is worsening.
TAGRISSO can be prescribed for you:
How TAGRISSO works
If you have any questions about how this medicine works or why this medicine has been prescribed for you, ask your doctor.
Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking TAGRISSO if:
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist, or nurse before taking this medicine.
Tell your doctor straight away while taking this medicine if:
Children and adolescents
TAGRISSO has not been studied in children or adolescents. Do not give this medicine to children or adolescents under the age of 18 years.
Other medicines and TAGRISSO
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes herbal medicines and medicines obtained without a prescription. This is because TAGRISSO can affect the way some other medicines work. Also, some other medicines can affect the way TAGRISSO works.
Tell your doctor before taking TAGRISSO if you are taking any of the following medicines:
The following medicines may reduce how well TAGRISSO works:
TAGRISSO may increase side effects of these medicines:
If you are taking any of the medicines listed above, tell your doctor before taking TAGRISSO.
Your doctor will discuss appropriate treatment options with you.
Pregnancy – information for women
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. If you do become pregnant during treatment, tell your doctor straight away. Your doctor will decide with you whether you should carry on taking TAGRISSO. You should not become pregnant while taking this medicine. If you are able to become pregnant, you must use effective contraception. See ‘Contraception – information for women and men’ below. If you plan to become pregnant after taking the last dose of this medicine, ask your doctor for advice. This is because some medicine may remain in your body.
Pregnancy – information for men
If your female partner becomes pregnant while you are taking this medicine, tell your doctor straight away.
Contraception – information for women and men
Women must use effective contraception during treatment.
Discuss with your doctor the most appropriate methods of contraception. TAGRISSO may pass into semen. Therefore, it is important that men also use effective contraception.
You must also do this after completing treatment with TAGRISSO:
Women – keep using contraception for 2 months after your last dose of TAGRISSO.
Men – keep using contraception for 4 months after your last dose of TAGRISSO.
Do not breast-feed while taking this medicine. This is because it is not known if there is a risk to your baby.
Driving and using machines
TAGRISSO has no or no marked influence on the ability to drive and use machines.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
How much to take
How to take
If you have trouble swallowing the tablet, you can dissolve it in water:
If you take more TAGRISSO than you should
If you take more than your normal dose, contact your doctor or nearest hospital straight away.
If you forget to take TAGRISSO
If you forget a dose, take it as soon as you remember it. However, if it is less than 12 hours until your next dose is due, skip the missed dose. Take your next normal dose at its scheduled time.
If you stop taking TAGRISSO
Do not stop taking this medicine – talk to your doctor first. It is important to take this medicine every day, for as long as your doctor prescribes it for you.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed on this website.
Serious side effects
Tell your doctor straight away if you notice the following serious side effects:
Tell your doctor straight away if you notice the serious side effect listed above.
Other side effects
Very common (may affect more than 1 in 10 people)
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed on this website. By reporting side effects, you can help provide more information on the safety of this medicine.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What TAGRISSO contains
What TAGRISSO looks like and contents of the pack
TAGRISSO 40 mg is supplied as beige, film-coated, round and biconvex tablets, marked with “AZ” and “40” on one side, and plain on the other.
TAGRISSO 80 mg is supplied as beige, film-coated, oval and biconvex tablets, marked with “AZ” and “80” on one side, and plain on the other.
TAGRISSO is supplied in blisters containing 30 x 1 film-coated tablets, packed in cartons containing 3 blisters strips of 10 tablets each.
TAGRISSO is supplied in blisters containing 28 x 1 film-coated packed in cartons containing 4 blisters of 7 tablets each.
European CanCer Organisation (ECCO)www.ecco-org.eu
Union for International Cancer Control (UICC)www.uicc.org
European Oncology Nursing Society (EONS)www.cancernurse.eu
International Association for the Study of Lung Cancer (IASLC)www.iaslc.org
European Society for Medical Oncology (ESMO)www.esmo.org
European Association for Cancer Research (EACR)www.eacr.org
International Agency for Research on Cancer (IARC)www.iarc.fr
Lung Cancer Europe (LuCE)www.lungcancereurope.eu
National Comprehensive Cancer Network® (NCCN®)www.nccn.org
American Society of Clinical Oncology (ASCO)www.asco.org
|Organisations offering support for patients|
European Cancer Patient Coalition (ECPC)www.ecpc.org
Global Lung Cancer Coalitionwww.lungcancercoalition.org
Lung Cancer Research Foundationwww.lungcancerresearchfoundation.org
Vital Options International (VOI)www.vitaloptions.org
European Lung Foundation (ELF)www.europeanlung.org
Roy Castle Lung Cancer Foundationwww.roycastle.org